Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
:AKBA
Total Valuation
Akebia Therapeutics has a market cap or net worth of $490.93M. The enterprise value is $794.19M.
Market Cap$490.93M
Enterprise Value$794.19M
Share Statistics
Akebia Therapeutics has 265,366,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding265,366,000
Owned by Insiders2.26%
Owned by Institutions0.19%
Financial Efficiency
Akebia Therapeutics’s return on equity (ROE) is 1.41 and return on invested capital (ROIC) is -34.77%.
Return on Equity (ROE)1.41
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-34.77%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee884.97K
Profits Per Employee-383.48K
Employee Count181
Asset Turnover0.73
Inventory Turnover3.89
Valuation Ratios
The current PE Ratio of Akebia Therapeutics is ―. Akebia Therapeutics’s PEG ratio is -0.32.
PE Ratio―
PS Ratio2.50
PB Ratio-8.15
Price to Fair Value-8.15
Price to FCF-9.85
Price to Operating Cash Flow15.37
PEG Ratio-0.32
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of 160.18M and earned -69.41M in profits. Earnings per share was -0.33.
Revenue160.18M
Gross Profit97.00M
Operating Income-50.47M
Pretax Income-69.41M
Net Income-69.41M
EBITDA-13.72M
Earnings Per Share (EPS)-0.33
Cash Flow
In the last 12 months, operating cash flow was 32.40M and capital expenditures -223.00K, giving a free cash flow of 32.17M billion.
Operating Cash Flow32.40M
Free Cash Flow32.17M
Free Cash Flow per Share0.12
Dividends & Yields
Akebia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.18
52-Week Price Change-5.38%
50-Day Moving Average2.68
200-Day Moving Average2.75
Relative Strength Index (RSI)30.31
Average Volume (3m)4.73M
Important Dates
Akebia Therapeutics upcoming earnings date is Mar 12, 2026, After Close (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 12, 2026
Ex-Dividend Date―
Financial Position
Akebia Therapeutics as a current ratio of 1.41, with Debt / Equity ratio of 512.82%
Current Ratio1.41
Quick Ratio1.21
Debt to Market Cap0.10
Net Debt to EBITDA0.31
Interest Coverage Ratio-2.78
Taxes
In the past 12 months, Akebia Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Akebia Therapeutics EV to EBITDA ratio is -28.90, with an EV/FCF ratio of -9.75.
EV to Sales2.48
EV to EBITDA-28.90
EV to Free Cash Flow-9.75
EV to Operating Cash Flow-9.75
Balance Sheet
Akebia Therapeutics has $166.44M in cash and marketable securities with $52.58M in debt, giving a net cash position of $113.87M billion.
Cash & Marketable Securities$166.44M
Total Debt$52.58M
Net Cash$113.87M
Net Cash Per Share$0.43
Tangible Book Value Per Share-$0.51
Margins
Gross margin is 78.99%, with operating margin of -31.51%, and net profit margin of -43.33%.
Gross Margin78.99%
Operating Margin-31.51%
Pretax Margin-43.33%
Net Profit Margin-43.33%
EBITDA Margin-8.57%
EBIT Margin-31.98%
Analyst Forecast
The average price target for Akebia Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.00
Price Target Upside240.91% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast32.49%
EPS Growth Forecast65.88%